This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Best And Worst Performing Biotech Stocks In the Second Quarter

IBB ChartIBB data by YCharts

BOSTON (TheStreet) -- Biotech investors will be happy with the chart above as the sector's benchmark index continues to outperform the broader market in the second quarter.

The iShares Nasdaq Biotechnology Index Fund closed the June quarter up 8.9 percent compared to a 2.8 percent rise in the S&P 500. The biotech index has been on a consistent downtrend since the middle of May, which bears watching.

Here are the five top-performing bio-pharma stocks in the second quarter:

No. 5: Vanda Pharmaceuticals (VNDA) VNDA ChartVNDA data by YCharts

Vanda is developing tasimelteon as a treatment for a rare sleep disorder which affects blind people. Vanda shares fell in June after questions were raised about the company's clinical development of tasimelteon, raising the risk that the drug would be rejected by FDA.

No. 4: Stemline Therapeutics (STML) STML ChartSTML data by YCharts

Stemline is developing drugs which target cancer stem cells. The company's shares rose following the presentation of clinical data at the American Society of Clinical Oncology annual meeting in early June.

No. 3: Immunomedics (IMMU) IMMU ChartIMMU data by YCharts

Immunomedics will be presenting results from a phase I study of the experimental radio-labeled monoclonal antibody Clivatuzumab tetraxetan at a medical meeting, July 3-6.

No. 2: Acadia Pharmaceuticals (ACAD) ACAD ChartACAD data by YCharts

Acadia continues to be one of the strongest-performing stocks in the biotech sector this year, supported by investor excitement for the company's Parkinson's psychosis drug pimavanserin.

No. 1: Clovis Oncology (ACAD) CLVS ChartCLVS data by YCharts

Clovis is not only the best-performing stock in the second quarter, but it's also No. 1 for all of 2013 so far. Why? The experimental lung cancer drug CO-1686.

Not all bio-pharma stocks enjoyed success in the second quarter. The worst-performing stocks for the June quarter were:

No. 5: Cardium Therapeutics (CXM) -56%
No. 4: Aveo Pharmaceuticals (AVEO) -66%
No. 3: Infinity Pharmaceuticals (INFI) -67%
No. 2: Echo Therapeutics (ECTE) -68%

No. 1: GenVec (GNVC): -75%

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs